

SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT  
PURSUANT TO SECTION 13 OR 15(d) OF  
THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): June 12, 2018

OptimizeRx Corporation  
(Exact name of registrant as specified in its charter)

Nevada

000-53605

26-1265381

(State or other jurisdiction  
of incorporation)

(Commission File Number)

(I.R.S. Employer  
Identification No.)

400 Water Street, Suite 200, Rochester, MI

48307

(Address of principal executive offices)

(Zip Code)

Registrant's telephone number, including area code: 248.651.6568

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

## **SECTION 8 – Other Events**

### **Item 8.01 Other Events**

On June 12, 2018, we issued a press release about our invitation to participate at the ROTH London Conference on June 19-20, 2018. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K.

The information in Item 8.01 of this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.

## **SECTION 9 – Financial Statements and Exhibits**

### **Item 9.01 Financial Statements and Exhibits**

99.1 [Press release, dated June 12, 2018](#)

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date June 13, 2018

**OptimizeRx Corporation**

/s/ Douglas Baker

Douglas Baker

Chief Financial Officer



### OptimizeRx to Participate at ROTH London Conference on June 19-20, 2018

**ROCHESTER, Mich., & London, U.K., (June 12, 2018)** — OptimizeRx Corp. (OTCQB: OPRX), the nation's leading provider of digital health messaging for the pharmaceutical industry, has been invited to participate at the ROTH London Conference being held on June 19-20, 2018 at the Dorchester Hotel in London, U.K.

OptimizeRx CEO William Febbo is scheduled to participate in one-on-one meetings. He will discuss a number of topics, including the company's record Q1 results and expanded exclusive partnership with Allscripts. He will also discuss the company's growing network that now reaches more than half of the ambulatory patient market in the U.S., and provide details around the company's new expansion into Europe through its partnership with UK-based Patient Connect.

The ROTH London Conference will give investors extensive interaction and one-on-one/small group meetings with management teams from ~50 small/mid-cap companies in the technology, cleantech and industrial sectors, and provide in-depth insights into each of them.

The event is for institutional clients of ROTH and is by invitation only. To schedule a one-on-one meeting with OptimizeRx, please contact your ROTH sales representative at (949) 720-5700 or [conference@roth.com](mailto:conference@roth.com). For any questions about OptimizeRx, contact Ron Both of CMA at (949) 432-7557 or submit your request [here](#).

#### About ROTH Capital Partners

ROTH Capital Partners, LLC is a relationship-driven investment bank focused on serving emerging growth companies and their investors. As a full-service investment bank, ROTH provides capital raising, M&A advisory, analytical research, trading, market-making services and corporate access. Headquartered in Newport Beach, CA, ROTH is privately-held and employee owned, and maintains offices throughout the U.S. For more information on ROTH, please visit [www.roth.com](http://www.roth.com).

#### About OptimizeRx

OptimizeRx® (OTCQB: OPRX) is one of the nation's leading providers of digital health messaging via electronic health records (EHRs), providing a direct channel for pharma companies to communicate with healthcare providers. The company's cloud-based solution supports patient adherence to medications by providing real-time access to financial assistance, prior authorization, education, and critical clinical information. The company's network is comprised of leading EHR platforms like Allscripts, Amazing Charts and Quest, and provides more than half of the ambulatory patient market with access to these benefits within their workflow at the point-of-care. For more information, follow the company on [Twitter](#), [LinkedIn](#) or visit [www.optimize.rx.com](http://www.optimize.rx.com).

#### Important Cautions Regarding Forward Looking Statements

This press release contains forward-looking statements within the definition of Section 27A of the Securities Act of 1933, as amended and such section 21E of the Securities Act of 1934, amended. These forward-looking statements should not be used to make an investment decision. The words 'estimate,' 'possible' and 'seeking' and similar expressions identify forward-looking statements, which speak only as to the date the statement was made. The company undertakes no obligation to publicly update or revise any forward-looking statements, whether because of new information, future events, or otherwise. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted, or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.

#### OptimizeRx Contact:

Doug Baker, CFO  
Tel (248) 651-6568 x807  
[dbaker@optimize.rx.com](mailto:dbaker@optimize.rx.com)

#### Investor Relations Contact for OptimizeRx:

Ron Both, CMA  
Tel (949) 432-7557  
[oprxcma@optimize.rx.com](mailto:oprxcma@optimize.rx.com)